USP18 promotes clear cell renal cell carcinoma progression by regulating the ubiquitination and stability of YBX3

, USP18 deficiency inhibits xenograft tumor growth by decreasing YBX3 expression and blocking the PI3K/AKT pathway. Our findings underscore the therapeutic potential of targeting the USP18-YBX3 axis in ccRCC treatment.